Wejse, Christian9, Østergaard, Lars Jørgen8, Laursen, Alex Lund8, Erikstrup, Christian7
1 Department of Clinical Medicine - Department of Clinical Immunology, Department of Clinical Medicine, Health, Aarhus University2 Department of Clinical Medicine - Department of Infectious Diseases, Department of Clinical Medicine, Health, Aarhus University3 Department of Public Health, Health, Aarhus University4 The Department of Infectious Diseases, Faculty of Health Sciences, Aarhus University, Aarhus University5 Department of Public Health - Department of Health Services Research, Department of Public Health, Health, Aarhus University6 unknown7 Department of Clinical Medicine - Department of Clinical Immunology, Department of Clinical Medicine, Health, Aarhus University8 Department of Clinical Medicine - Department of Infectious Diseases, Department of Clinical Medicine, Health, Aarhus University9 Department of Public Health - Department of Health Services Research, Department of Public Health, Health, Aarhus University
OBJECTIVE: We describe the association between age at antiretroviral therapy (ART) initiation and 24-month CD4 cell response in West African HIV-infected children. METHODS: All HIV-infected children from the IeDEA paediatric West African cohort, initiating ART, with at least two CD4 cell count measurements, including one at ART initiation (baseline) were included. CD4 cell gain on ART was estimated using a multivariable linear mixed model adjusted for baseline variables: age, CD4 cell count, sex, first-line ART regimen. Kaplan-Meier survival curves and a Cox proportional hazards regression model compared immune recovery for age within 24 months post-ART. RESULTS: Of the 4808 children initiated on ART, 3014 were enrolled at a median age of 5.6 years; 61.2% were immunodeficient. After 12 months, children at least 4 years at baseline had significantly lower CD4 cell gains compared with children less than 2 years, the reference group (P<0.001). However, by 24 months, we observed higher CD4 cell gain in children who initiated ART between 3 and 4 years compared with those less than 2 years (P<0.001). The 24-month CD4 cell gain was also strongest in immunodeficient children at baseline. Among these children, 75% reached immune recovery: 12-month rates were significantly highest in all those aged 2-5 years at ART initiation compared with those less than 2 years. Beyond 12 months on ART, immune recovery was significantly lower in children initiated more than 5 years (adjusted hazard ratio: 0.69, 95% confidence interval: 0.56-0.86). CONCLUSION: These results suggest that both the initiation of ART at the earliest age less than 5 years and before any severe immunodeficiency is needed for improving 24-month immune recovery on ART.
Aids, 2014, Vol 28, Issue 11, p. 1645-55
Africa, Western; Age Factors; Anti-Retroviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Male; Sex Factors; Treatment Outcome